Stem cells for cardiac repair in acute myocardial infarction

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 8, 2011, Pages 1015-1025

  Beitnes, Jan Otto ^a   Lunde, Ketil ^a   Brinchmann, Jan E ^a,b   Aakhus, Svend ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

bone marrow cells; cell therapy; MSCs; myocardial infarction; tissue engineering

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; VASCULOTROPIN;

ACUTE HEART INFARCTION; CELL REGENERATION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HUMAN; MESENCHYMAL STEM CELL; MONONUCLEAR CELL; NONHUMAN; PLURIPOTENT STEM CELL; REVIEW; STABLE ANGINA PECTORIS; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING;

ADULT; ADULT STEM CELLS; ANIMALS; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; HUMANS; LEUKOCYTES, MONONUCLEAR; MESENCHYMAL STEM CELL TRANSPLANTATION; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; STEM CELL TRANSPLANTATION;

EID: 80052436466     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.108     Document Type: Review

References (97)

1. Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 121(7), e46-e215 (2010).
2. Heidenreich PA, Trogdon JG, Khavjou OA et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123(8), 933-944 (2011).
3. Marelli D, Desrosiers C, el-Alfy M, Kao RL, Chiu RC. Cell transplantation for myocardial repair: an experimental approach. Cell Transplant. 1(6), 383-390 (1992).
4. Linzbach AJ. Heart failure from the point of view of quantitative anatomy. Am. J. Cardiol. 5, 370-382 (1960).
5. Soonpaa MH, Field LJ. Survey of studies examining mammalian cardiomyocyte DNA synthesis. Circ. Res. 83(1), 15-26 (1998).
6. Bergmann O, Bhardwaj RD, Bernard S et al. Evidence for cardiomyocyte renewal in humans. Science 324(5923), 98-102 (2009).
7. Kajstura J, Gurusamy N, Ogorek B et al. Myocyte turnover in the aging human heart. Circ. Res. 107(11), 1374-1386 (2010).
8. Van de Werf F, Bax J, Betriu A et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur. Heart J. 29(23), 2909-2945 (2008).
9. Dimmeler S, Aicher A, Vasa M et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest. 108(3), 391-397 (2001).
10. Landmesser U, Engberding N, Bahlmann FH et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110(14), 1933-1939 (2004).
11. Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 45(4), 526-529 (2005).
12. Wang CH, Verma S, Hsieh IC et al. Enalapril increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system. J. Mol. Cell. Cardiol. 41(1), 34-43 (2006).
13. Bahlmann FH, de Groot K, Spandau JM et al. Erythropoietin regulates endothelial progenitor cells. Blood 103(3), 921-926 (2004).
14. Yanagisawa-Miwa A, Uchida Y, Nakamura F et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 257(5075), 1401-1403 (1992).
15. Sugano Y, Anzai T, Yoshikawa T et al. Granulocyte colony-stimulating factor attenuates early ventricular expansion after experimental myocardial infarction. Cardiovasc. Res. 65(2), 446-456 (2005).
16. Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H, Nakamura T. Myocardial protection from ischemia/ reperfusion injury by endogenous and exogenous HGF. J. Clin. Invest. 106(12), 1511-1519 (2000).
17. Padin-Iruegas ME, Misao Y, Davis ME et al. Cardiac progenitor cells and biotinylated insulin-like growth factor-1 nanofibers improve endogenous and exogenous myocardial regeneration after infarction. Circulation 120(10), 876-887 (2009).
18. Zaruba MM, Huber BC, Brunner S et al. Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival. Cardiovasc. Res. 77(4), 722-731 (2008).
19. Saxena A, Fish JE, White MD et al. Stromal cell-derived factor-1a is cardioprotective after myocardial infarction. Circulation 117(17), 2224-2231 (2008).
20. Pearlman JD, Hibberd MG, Chuang ML et al. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nat. Med. 1(10), 1085-1089 (1995).
21. Segers VF, Lee RT. Protein therapeutics for cardiac regeneration after myocardial infarction. J. Cardiovasc. Transl. Res. 5(3), 469-477 (2010).
22. Zohlnhofer D, Dibra A, Koppara T et al. Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis. J. Am. Coll. Cardiol. 51(15), 1429-1437 (2008).
23. Henry TD, Annex BH, McKendall GR et al. The VIVA trial: Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis. Circulation 107(10), 1359-1365 (2003).
24. Kastrup J, Jorgensen E, Ruck A et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris. A randomized double-blind placebo-controlled study: the Euroinject One trial. J. Am. Coll. Cardiol. 45(7), 982-988 (2005).
25. Mummery CL, Davis RP, Krieger JE. Challenges in using stem cells for cardiac repair. Sci. Transl. Med. 2(27), 27ps17 (2010).
26. Vidarsson H, Hyllner J, Sartipy P. Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications. Stem Cell Rev. 6, 108-120 (2010).
27. Menard C, Hagege AA, Agbulut O et al. Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: a preclinical study. Lancet 366(9490), 1005-1012 (2005).
28. Laflamme MA, Gold J, Xu C et al. Formation of human myocardium in the rat heart from human embryonic stem cells. Am. J. Pathol. 167(3), 663-671 (2005).
29. Cao F, Lin S, Xie X et al. In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation 113(7), 1005-1014 (2006).
30. Cai J, Yi FF, Yang XC et al. Transplantation of embryonic stem cell-derived cardiomyocytes improves cardiac function in infarcted rat hearts. Cytotherapy 9(3), 283-291 (2007).
31. Qiao H, Zhang H, Yamanaka S et al. Long-term improvement in post-infarct left ventricular global and regional contractile function mediated by embryonic stem cell-derived cardiomyocytes. Circ. Cardiovasc. Imaging 4(1), 33-41 (2011).
32. Tomescot A, Leschik J, Bellamy V et al. Differentiation in vivo of cardiac committed human embryonic stem cells in post-myocardial infarcted rats. Stem Cells 9(25), 2200-2205 (2007).
33. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 474(7350), 212-215 (2011).
34. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4), 663-676 (2006).
35. Ahmed RP, Ashraf M, Buccini S, Shujia J, Haider HK. Cardiac tumorgenic potential of induced pluripotent stem cells in an immunocompetent host with myocardial infarction. Regen. Med. 6(2), 171-178 (2011).
36. Lister R, Pelizzola M, Kida YS et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 471(7336), 68-73 (2011).
37. Gore A, Li Z, Fung HL et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 471(7336), 63-67 (2011).
38. Martinez-Fernandez A, Nelson TJ, Ikeda Y, Terzic A. c-MYC independent nuclear reprogramming favors cardiogenic potential of induced pluripotent stem cells. J. Cardiovasc. Transl. Res. 3(1), 13-23 (2010).
39. Pera MF. Stem cells: The dark side of induced pluripotency. Nature 471(7336), 46-47 (2011).
40. de la Grandmaison GL, Clairand I, Durigon M. Organ weight in 684 adult autopsies: new tables for a Caucasoid population. Forensic Sci. Int. 119(2), 149-154 (2001).
41. Sebkhi A, Zhao L, Lu L, Haley CS, Nunez DJ, Wilkins MR. Genetic determination of cardiac mass in normotensive rats: results from an F344xWKY cross. Hypertension 33(4), 949-953 (1999).
42. Schachinger V, Aicher A, Dobert N et al. Pilot trial on determinants of progenitor cell recruitment to the infarcted human myocardium. Circulation 118(14), 1425-1432 (2008).
43. Perin EC, Silva GV, Assad JA et al. Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction. J. Mol. Cell Cardiol. 44(3), 486-495 (2007).
44. Baldazzi F, Jorgensen E, Ripa RS, Kastrup J. Release of biomarkers of myocardial damage after direct intramyocardial injection of genes and stem cells via the percutaneous transluminal route. Eur. Heart J. 29(15), 1819-1826 (2008).
45. Krause K, Jaquet K, Schneider C et al. Percutaneous intramyocardial stem cell injection in patients with acute myocardial infarction. First-in-man study. Heart 95(14), 1145-1152 (2009).
46. Friis T, Haack-Sorensen M, Mathiasen AB et al. Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory angina. Scand. Cardiovasc. J. 45(3), 161-168 (2011).
47. Mazo M, Planat-Benard V, Abizanda G et al. Transplantation of adipose derived stromal cells is associated with functional improvement in a rat model of chronic myocardial infarction. Eur. J. Heart Fail. 10(5), 454-462 (2008).
48. Arminan A, Gandia C, Garcia-Verdugo JM et al. Mesenchymal stem cells provide better results than hematopoietic precursors for the treatment of myocardial infarction. J. Am. Coll. Cardiol. 55(20), 2244-2253 (2010).
49. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105(1), 93-98 (2002).
50. Beitnes JO, Oie E, Shahdadfar A et al. Intramyocardial injections of human mesenchymal stem cells following acute myocardial infarction modulate scar formation and improve left ventricular function. Cell Transplant. (2011) (In Press).
51. Murry CE, Reinecke H, Pabon LM. Regeneration gaps: observations on stem cells and cardiac repair. J. Am. Coll. Cardiol. 47(9), 1777-1785 (2006).
52. Simpson D, Liu H, Fan TH, Nerem R, Dudley SC Jr. A tissue engineering approach to progenitor cell delivery results in significant cell engraftment and improved myocardial remodeling. Stem Cells 25(9), 2350-2357 (2007).
53. Sekiya N, Matsumiya G, Miyagawa S et al. Layered implantation of myoblast sheets attenuates adverse cardiac remodeling of the infarcted heart. J. Thorac. Cardiovasc. Surg. 138(4), 985-993 (2009).
54. Bel A, Planat-Bernard V, Saito A et al. Composite cell sheets: a further step toward safe and effective myocardial regeneration by cardiac progenitors derived from embryonic stem cells. Circulation 122(Suppl. 11), S118-S123 (2010).
55. Stevens KR, Pabon L, Muskheli V, Murry CE. Scaffold-free human cardiac tissue patch created from embryonic stem cells. Tissue Eng. Part A 15(6), 1211-1222 (2008).
56. Zimmermann WH, Melnychenko I, Wasmeier G et al. Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat. Med. 12(4), 452-458 (2006).
57. Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infarcted myocardium. Nature 410(6829), 701-705 (2001).
58. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 284(5411), 143-147 (1999).
59. Taylor DA, Atkins BZ, Hungspreugs P et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat. Med. 4(8), 929-933 (1998).
60. Dowell JD, Rubart M, Pasumarthi KBS, Soonpaa MH, Field LJ. Myocyte and myogenic stem cell transplantation in the heart. Cardiovasc. Res. 58(2), 336-350 (2003).
61. Leobon B, Garcin I, Menasche P, Vilquin JT, Audinat E, Charpak S. Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their host. Proc. Natl Acad. Sci. USA 100(13), 7808-7811 (2003).
62. Fernandes S, Amirault JC, Lande G et al. Autologous myoblast transplantation after myocardial infarction increases the inducibility of ventricular arrhythmias. Cardiovasc. Res. 69(2), 348-358 (2006).
63. Menasche P, Alfieri O, Janssens S et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 117(9), 1189-1200 (2008).
64. Beltrami AP, Barlucchi L, Torella D et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114(6), 763-776 (2003).
65. Smith RR, Barile L, Cho HC et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 115(7), 896-908 (2007).
66. D'Amario D, Fiorini C, Campbell PM et al. Functionally competent cardiac stem cells can be isolated from endomyocardial biopsies of patients with advanced cardiomyopathies. Circ. Res. 108(7), 857-861 (2011).
67. Porrello ER, Mahmoud AI, Simpson E et al. Transient regenerative potential of the neonatal mouse heart. Science 331(6020), 1078-1080 (2011).
68. Crisan M, Chen CW, Corselli M, Andriolo G, Lazzari L, Peault B. Perivascular multipotent progenitor cells in human organs. Ann. NY Acad. Sci. 1176, 118-123 (2009).
69. Hare JM, Traverse JH, Henry TD et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J. Am. Coll. Cardiol. 54(24), 2277-2286 (2009).
70. Lee RH, Pulin AA, Seo MJ et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6 Cell Stem Cell 5(1), 54-63 (2009).
71. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103(12), 4619-4621 (2004).
72. Ren G, Zhang L, Zhao X et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2(2), 141-150 (2008).
73. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a Phase II study. Lancet 371(9624), 1579-1586 (2008).
74. Le Blanc K, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 11(5), 321-334 (2005).
75. Behfar A, Yamada S, Crespo-Diaz R et al. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J. Am. Coll. Cardiol. 56(9), 721-734 (2010).
76. Bartunek J, Wijns W, Dolatabadi D et al. C-CURE multicenter trial: lineage specified bone marrow derived cardiopoietic mesenchymal stem cells for treatment of ischemic cardiomyopathy. J. Am. Coll. Cardiol. 57(Suppl. 14), E200 (2011).
77. Theise ND, Nimmakayalu M, Gardner R et al. Liver from bone marrow in humans. Hepatology 32(1), 11-16 (2000).
78. Mezey E, Chandross KJ, Harta G, Maki RA, McKercher SR. Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. Science 290(5497), 1779-1782 (2000).
79. Tomita S, Li RK, Weisel RD et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 100(19 Suppl.), II247-II256 (1999).
80. Balsam LB, Robbins RC. Haematopoietic stem cells and repair of the ischaemic heart. Clin. Sci. 109(6), 483-492 (2005).
81. Murry CE, Soonpaa MH, Reinecke H et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428(6983), 664-668 (2004).
82. Nygren JM, Jovinge S, Breitbach M et al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat. Med. 10(5), 494-501 (2004).
83. Strauer BE, Brehm M, Zeus T et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106(15), 1913-1918 (2002).
84. Martin-Rendon E, Brunskill S, Doree C et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst. Rev. 4, CD006536 (2008).
85. Wollert KC, Meyer GP, Lotz J et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 364(9429), 141-148 (2004).
86. Meyer GP, Wollert KC, Lotz J et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (Bone Marrow Transfer to Enhance ST-elevation Infarct Regeneration) trial. Circulation 113(10), 1287-1294 (2006).
87. Meyer GP, Wollert KC, Lotz J et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur. Heart J. 30(24), 2978-2984 (2009).
88. Schachinger V, Erbs S, Elsasser A et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 355(12), 1210-1221 (2006).
89. 4+ Cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur. Heart J. 30(11), 1313-1321 (2009).
90. Hirsch A, Nijveldt R, van de V et al. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronaryintervention: results of the randomized controlled HEBE trial. Eur. Heart J. 32(14), 1736-1747 (2011).
91. Penicka M, Horak J, Kobylka P et al. Intracoronary injection of autologous bone marrow-derived mononuclear cells in patients with large anterior acute myocardial infarction: a prematurely terminated randomized study. J. Am. Coll. Cardiol. 49(24), 2373-2374 (2007).
92. Wohrle J, Merkle N, Mailander V et al. Results of intracoronary stem cell therapy after acute myocardial infarction. Am. J. Cardiol. 105(6), 804-812 (2010).
93. Lunde K, Solheim S, Aakhus S et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N. Engl. J. Med. 355(12), 1199-1209 (2006).
94. Beitnes JO, Hopp E, Lunde K et al. Long term results after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction. The ASTAMI randomized, controlled study. Heart 95(24), 1983-1989 (2009).
95. Schachinger V, Erbs S, Elsasser A et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur. Heart J. 27(23), 2775-2783 (2006).
96. Arnesen H, Lunde K, Aakhus S, Forfang K. Cell therapy in myocardial infarction. Lancet 369(9580), 2142-2143 (2007).
97. Lunde K, Aakhus S. Bone marrow-derived stem cells for treatment of ischemic heart disease: background and experience from clinical trials. In:Handbook of Cardiac Stem Cell Therapy. Dimarakis I (Ed.). Imperial College Press, London, UK (2009).